This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
by Zacks Equity Research
Conatus (CNAT) concentrates on the development of its lead candidate emricasan for treating patients with fibrosis or cirrhosis caused by NASH.
Has Bovie Medical (BVX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BVX) Outperforming Other Medical Stocks This Year?
Quidel (QDEL) Catches Eye: Stock Jumps 6.7%
by Zacks Equity Research
Quidel (QDEL) shares rose nearly 7% in the last trading session, amid huge volumes.
Why Varex Imaging (VREX) Could Be Positioned for a Slump
by Zacks Equity Research
Varex Imaging (VREX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
by Zacks Equity Research
Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.
Will Bovie Medical (BVX) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Bovie Medical Corporation (BVX).
What Makes Bovie Medical (BVX) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Bovie Medical (BVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks.com highlights: WillScot, Primerica, Bovie Medical, Shenandoah Telecommunications and Herbalife Nutrition
by Zacks Equity Research
Zacks.com highlights: WillScot, Primerica, Bovie Medical, Shenandoah Telecommunications and Herbalife Nutrition
Snap Up These 5 Stocks on New Analyst Coverage
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
Implied Volatility Surging for Bovie Medical (BVX) Stock Options
by Zacks Equity Research
Bovie Medical (BVX) needs investors to pay close attention to the stock based on moves in the options market lately.
Do Options Traders Know Something About Bovie Medical (BVX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Bovie Medical (BVX) stock based on the movements in the options market lately.
Align Partners Zfx GmbH to Expand iTero Scanner Business
by Zacks Equity Research
Align Technology Inc. (ALGN) announced a non-exclusive agreement with digital prosthetic solutions maker, Zfx GmbH on iTero Element intraoral scanners.
VWR Corp Acquires EPL Archives, Improves Customer Service
by Zacks Equity Research
VWR Corporation (VWR) recently acquired the international biorepository services organization, EPL Archives, Inc.
Walgreen Boots Buyout of Rite Aid Delayed, Other Woes Remain
by Zacks Equity Research
On Mar 24, we issued an updated research report on Illinois-based leading pharmacy-led, health and wellbeing enterprise, Walgreens Boots Alliance, Inc. (WBA).
Align's iTero Hits 1 Billion Mark, Boosts Scanner Business
by Zacks Equity Research
Align Technology Inc. (ALGN) has recently revealed that more than one million scans have been submitted using its iTero Element scanner in less than two years.
MedTech Long-Term Prospects Impress: Which Stocks to Buy?
by Zacks Equity Research
President Trump will finally replace the ACA and implement his own strategy, the nation is clearly divided into "we need" and "don't need" camps.
Integer (ITGR) Amends Term B Loan to Lower Interest Rate
by Zacks Equity Research
Integer Holdings Corporation (ITGR) announced that it has completed an amendment to its senior secured credit facilities to lower the interest rate on its Term B Loan Facility.
Bovie Medical (BVX) is Oversold: Can It Recover?
by Zacks Equity Research
Bovie Medical Corporation (BVX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Why Bovie Medical (BVX) Could Be an Impressive Growth Stock
by Zacks Equity Research
Bovie Medical (BVX) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Growth perspective.
New Strong Buy Stocks for February 10th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Strength Seen in Bovie Medical (BVX): Stock Moves 5% Higher
by Zacks Equity Research
Bovie Medical Corporation (BVX) was a big mover last session, as the company saw its shares rise around 5% on the day.
What Makes Meridian Bioscience (VIVO) a Strong Sell?
by Zacks Equity Research
Meridian Bioscience (VIVO), has witnessed a significant price decline and negative trend in earnings estimate revisions
Zimmer Biomet (ZBH): Spine Group Solid, Q3 Results a Drag
by Zacks Equity Research
On Dec 19, we issued an updated research report on Warsaw, IN-based Zimmer Biomet Holdings Inc. (ZBH).
Zimmer Biomet (ZBH) Reveals Positive Hip Arthroplasty Data
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) declared that, the National Joint Registry (NJR) for England, Wales, Northern Ireland and the Isle of Man documented favorable outcome on its Trabecular Metal Cups.
Zimmer Biomet (ZBH) Launches PrimaGen Advanced Allograft
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) recently launched PrimaGen Advanced Allograft which has been designed to be used as an allogeneic bone graft substitute.